Tryton Medical is the leading developer of stents designed to treat coronary bifurcation lesions. Its core product, the Tryton Side Branch Stent System, uses proprietary Tri‑ZONE® technology and a cobalt‑chromium design deployed in the side branch via a standard single‑wire balloon‑expandable delivery system while a conventional drug‑eluting stent is placed in the main vessel. The Tryton Side Branch Stent has been used to treat more than 10,000 patients worldwide, is commercially available in multiple countries across Europe, the Middle East & Africa, is investigational in the U.S., and is not available in Japan. Tryton is pursuing U.S. market clearance through the Pivotal IDE Trial and the Tryton IDE Extended Access Registry, with results from both intended for submission to the FDA. The company plans to develop the left main market opportunity based on a CE approved left main stent indication for its Tryton Side Branch Stent. Tryton completed an initial closing of a $20 million private equity financing to support registry enrollment, the FDA submission, and left main market development. Tryton Medical develops stent systems to treat coronary bifurcation lesions using its proprietary Tri-zone technology. Its cobalt chromium stent is deployed in the side branch with a standard single-wire balloon-expandable delivery system, after which a conventional drug-eluting stent is placed in the main vessel. The stent system has received CE Mark and is commercially available across Europe, Russia and the Middle East, while in the United States it is approved for investigational use only. The company, founded in 2003 and led by president and CEO Shawn P. McCarthy, intends to support a U.S. FDA submission this year and to expand its platform with a new stent system targeting left main disease. Tryton also plans to accelerate access into critical global markets, specifically in Asia. It recently held an initial closing of an aggregate $24M financing to support those plans. Tryton Medical, located in Durham, NC, develops novel stent systems for the treatment of coronary bifurcation lesions. Its Tryton Side Branch Stent System has CE Mark approval in Europe and has been implanted in more than 2,500 patients. The company was founded in 2003 by Aaron V. Kaplan, M.D., and Dan Cole. Tryton is privately held and venture-backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. Square 1 Bank has extended a $5 million term loan credit facility to the company. With the new facility, Tryton is enrolling in a pivotal U.S. clinical trial to advance its device toward broader market access. Tryton Medical develops the Tryton Side Branch Stent System, a dedicated strategy for treating atherosclerotic lesions in the side branch at coronary bifurcations. The system has shown excellent six-month clinical and angiographic results in a first-in-man study and similarly strong six-month clinical outcomes from nearly 200 patients across four registries, with a target lesion revascularization rate under 4%. The device has received CE Mark approval and is commercially available in 21 countries across Europe and the Middle East. It is not approved for use in the United States. The company plans to use new financing to conduct a U.S. pivotal trial and to drive broader international product adoption. Tryton is based in Durham, North Carolina.

Total raised

$69M

Funding rounds

4

Latest round

Equity

Latest activity

Sep 2014